Biomarkers in Chronic Rhinosinusitis: Current Evidence and Clinical Implications

Abstract

Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory disease of the nasal and paranasal mucosa, presenting significant diagnostic and therapeutic challenges. Recent research has focused on the identification and validation of biomarkers to facilitate disease endotyping, predict treatment response, and guide personalized management. This review synthesizes current evidence regarding the role of biomarkers in CRS, encompassing epidemiology, pathophysiology, risk stratification, clinical features, diagnostic utility, therapeutic implications, and recent advances. Emphasis is placed on clinically actionable insights and guideline-based recommendations for practicing clinicians.

Introduction

Chronic rhinosinusitis affects millions worldwide, imposing a substantial burden on quality of life and healthcare systems. The clinical spectrum of CRS is broad, encompassing multiple phenotypes and endotypes, each with distinct immunopathologic signatures. Biomarkers have emerged as critical tools for improving disease characterization, stratifying risk, and optimizing therapeutic strategies. This article provides a comprehensive overview of biomarkers in CRS, integrating recent research and clinical guidelines to inform evidence-based practice.

Epidemiology / Disease Burden

CRS affects approximately 12% of the general population, with prevalence estimates varying according to diagnostic criteria and geographic region. The disease is associated with significant morbidity, including impaired olfaction, persistent nasal obstruction, facial pain, and recurrent infections. Direct and indirect healthcare costs are considerable, driven by medical consultations, pharmacotherapy, surgical interventions, and productivity loss. Importantly, CRS contributes to comorbid conditions such as asthma, highlighting the need for improved diagnostic and management approaches through biomarker integration.

Pathophysiology

CRS pathogenesis is multifactorial, involving a complex interplay between host immune responses, environmental triggers, and microbial factors. Two major phenotypes CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP) are recognized, each characterized by distinct inflammatory patterns. Type 2 inflammation, driven by eosinophils, Th2 lymphocytes, and cytokines such as IL-4, IL-5, and IL-13, predominates in CRSwNP, while neutrophilic inflammation is more common in CRSsNP. This immunological heterogeneity underpins the search for reliable biomarkers to distinguish endotypes and inform targeted therapy.

Risk Factors

Multiple risk factors contribute to CRS development, including genetic predisposition, atopy, asthma, environmental exposures (e.g., tobacco smoke, pollutants), and anatomical variations. The presence of comorbid conditions such as allergic rhinitis, aspirin-exacerbated respiratory disease (AERD), and immunodeficiency further modulates disease course and therapeutic response. Biomarkers may assist in identifying individuals at heightened risk and in predicting disease progression or recurrence post-intervention.

Clinical Features

The clinical presentation of CRS encompasses persistent sinonasal symptoms for at least 12 weeks, including nasal blockage, rhinorrhea, facial pain/pressure, and reduced sense of smell. Phenotypic differentiation between CRSwNP and CRSsNP is crucial, as it correlates with underlying immunopathology and therapeutic response. Biomarkers such as tissue eosinophil count, serum periostin, and nasal cytokine profiles have shown potential in correlating with symptom severity, polyp burden, and risk of recurrence, supporting their integration into clinical assessment.

Diagnosis

CRS diagnosis is based on clinical criteria, nasal endoscopy, and radiological findings (e.g., Lund-Mackay scoring on CT). However, these modalities are limited in differentiating endotypes and predicting treatment outcomes. Biomarkers are increasingly investigated for their diagnostic utility. For instance, elevated tissue or peripheral blood eosinophils, increased levels of IL-5, and S100 proteins (such as S100A8/A9) have been associated with type 2 CRS and polyp recurrence. Measurement of exhaled nitric oxide (FeNO) and local IgE levels may further aid in disease stratification, particularly in differentiating allergic and non-allergic endotypes.

Treatment & Management

Standard CRS management includes intranasal corticosteroids, saline irrigation, antibiotics (when indicated), and surgical intervention for refractory cases. The advent of biologic therapies targeting specific inflammatory pathways (e.g., anti-IL-5, anti-IL-4Rα, anti-IgE) heralds a new era of personalized care. Biomarkers are essential in identifying patients likely to benefit from these treatments. For example, elevated eosinophil counts and type 2 cytokine signatures predict favorable response to anti-IL-5 or anti-IL-4Rα agents. Conversely, neutrophilic or type 1/type 3 inflammation may warrant alternative strategies, such as macrolide therapy or immunomodulation.

Recent Advances / Emerging Therapies

Technological advances in omics platforms (transcriptomics, proteomics, metabolomics) have accelerated biomarker discovery in CRS. Novel candidates such as periostin, eotaxin-3, and TSLP are under evaluation in clinical trials for their ability to predict disease trajectory and treatment response. Liquid biopsy approaches, including analysis of nasal secretions and exhaled breath condensate, offer minimally invasive biomarker assessment. Machine learning and artificial intelligence are increasingly leveraged to integrate multidimensional biomarker data, improving diagnostic accuracy and enabling robust endotyping for precision medicine applications.

Guideline Recommendations

Recent international guidelines emphasize the importance of endotype-driven management in CRS. The European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS 2020) and the International Consensus Statement on Allergy and Rhinology recommend the integration of biomarkers such as tissue eosinophilia, serum IgE, and cytokine profiling to guide biologic therapy selection. Routine biomarker testing is currently limited to research settings or specialized centers, but ongoing validation efforts may soon enable broader clinical adoption. Clinicians are encouraged to consider biomarker data in the context of individual patient characteristics and comorbidities.

Conclusion

Biomarkers represent a transformative advance in the management of chronic rhinosinusitis, offering opportunities for improved disease characterization, risk stratification, and personalized therapy. Ongoing research continues to expand the repertoire of clinically relevant biomarkers, with emerging evidence supporting their integration into routine practice. As technologies evolve and guideline recommendations mature, biomarker-driven strategies are poised to enhance outcomes and quality of life for patients with CRS. Multidisciplinary collaboration among clinicians, researchers, and laboratory specialists will be essential to realize the full potential of biomarkers in this complex disease.